Pay in 4 interest-free payments of $5.14 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
These reactions are usually mild and not common, but in some people, they can become bothersome or persistent
Scientific Research Review SURPASS Clinical Trial Program (Type 2 Diabetes) The SURPASS program comprised phase III trials evaluating tirzepatide 5, 10, and 15 mg once weekly in patients with type 2 diabetes: SURPASS-1 (monotherapy, n=478): Tirzepatide reduced HbA1c by 1.87% (5 mg), 1.89% (10 mg), and 2.07% (15 mg) vs
Review medications: Some medications (certain antidepressants, antipsychotics, steroids) promote weight gain and may counteract semaglutide effects
T2D management costs were sourced from a prospective cohort study in China (Li et al., 2019)
Beyond raw weight loss numbers, Retatrutide produced meaningful metabolic improvements in trial participants
US$ 26.12
US$ 25.99
US$ 20.93
US$ 29.28
US$ 28.36
US$ 23.43
US$ 24.84
US$ 25.50
US$ 29.51
